Journal for ImmunoTherapy of Cancer

Researchers from Osaka University found that tetracycline antibiotics stimulate T lymphocytes in the body’s immune system to attack and destroy cancer cells. The antibiotics work by blocking the action of galactin-1, a protein made by cancer cells that suppresses the immune system. Identification of this new target may lead to the development of novel cancer immunotherapies.

Cancer stem cells cause the aging of macrophages in mice with healthy immune systems, creating conditions for the formation of tumors.

A specially designed lipid nanoparticle could deliver immune-signaling molecules into liver macrophage cells to overcome resistance to anti-tumor immunotherapy.